MODERATORS

Hope Rugo, MD, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, Medical Director of Cancer Infusion Services, UCSF Helen DIller Family Comprehensive Cancer Center

Laura Crocitto, MD, Vice President and Chief Medical Officer for Cancer Services, Medical Director, UCSF Helen Diller Family Comprehensive Cancer Center

-------

PRESENTATIONS

"Breast Oncology"

Jo Chien, MD, Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center

Tiffany Svahn, MD, Medical Director of Oncology, John Muir Health President, John Muir Health Cancer Medical Group

Upon completion of this course, participants will have improved their skills and strategies for:

• Understanding the role of adjuvant CDK 4/6 inhibitors in high-risk earlystage hormone-receptor -positive breast cancer.
• Understanding current and potential treatment options for HR+ HER2- negative metastatic breast cancer post-CDK 4/6 inhibitors.

-------

"Lung Oncology"

Michael L. Cheng, MD, Assistant Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center

Gigi Chen, MD, Medical Director of Oncology Research, John Muir Health Cancer Medical Group

Upon completion of this course, participants will have improved their skills and strategies for:

• Summarizing updates in lung cancer early detection.
• Understanding the overall survival benefit trial in resected EGFR mutationpositive non-small cell lung cancer treated in the ADURA trial.
• Summarizing recent trials in preoperative immunotherapy and chemotherapy for resectable non-small cell lung cancer.

-------

"Gastrointestinal Oncology"

Geoffrey Buckle, MD, MPH, Assistant Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center

Tianyi Tang, MD, PhD, Hematology/Medical Oncology, John Muir Health Cancer Medical Group

Upon completion of this course, participants will have improved their skills and strategies for:

• Summarize key findings related to recent clinical trials focused on deintensification strategies for the treatment of locally advanced rectal cancer, with a specific focus on long-term results of the PROSPECT and OPRA trials.
• Discuss the implications of the latest trial results on current guidelines and best practices for the management of locally advanced rectal cancer.

-------

"Hematologic Oncology"

Madhav Seshadri, MD, Assistant Professor of Medicine Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, UCSF Helen Diller Family Comprehensive Cancer Center

Yelena Krupitskaya, MD, Hematology/Medical Oncology, John Muir Health Cancer Medical Group

Upon completion of this course, participants will have improved their skills and strategies for:

• Understanding the data supporting approved bispecific antibody therapies for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
• Understanding patient selection and sequencing of bispecific antibodies in relation to other approved therapies.

-------

REGISTRATION

To secure your spot, please register in advance. 

• REGISTER WITH CME
• REGISTER WITHOUT CME